Drug discovery is hard. In fact, approximately, only 11% of new drugs that enter clinical trials make it to the US market. For central nervous system (CNS) drugs, which includes Alzheimer's, this rate is even lower - only about 8%. The most troubling trend is the rate of failure for Alzheimer's drugs in Phase 3, the final step of the drug development process before regulatory submission.

This session will discuss innovative approaches to clinical trial design, and the use of companion diagnostic testing and biomarkers, to improve the success of clinical trials in Alzheimer's disease and mild cognitive impairment.